Execs from Inovio Biomedical Corporation and Novavax will be speaking at BIF about their experience in the race to develop a vaccine for H1N1. Below are a couple recent developments from these companies:

  • Novavax Inc (NVAX.O) recently reported that its seasonal flu vaccine candidate, which uses virus-like particles, induced an immune response against H3N2, H1N1 and B and was well-tolerated in a mid-stage trial. Read the release.
  • Inovio Biomedical Corp. (INO) said it will team up with the National Institutes of Health’s vaccine-research center to create influenza vaccines and expedite development of an H1N1 vaccine as the pandemic spreads. Read the release.
Advertisements